Danaher Q2 FY2026: adjusted EPS $1.94 beats, guidance raised
Danaher's second quarter beat on the bottom line and management raised full-year profit guidance, so the quarter reads Bullish despite a softer gross margin. Revenue rose 5.5% to $6.265 billion and adjusted EPS of $1.94 topped the $1.8533 consensus, while GAAP EPS jumped 60%. The catch is a 57.6% gross margin, down from 59.3% a year ago and 60.3% last quarter.
1 · Expected vs. Actual
Free preview belowGAAP EPS of $1.23 was up 60% from $0.77, though last year's quarter carried a $0.60 impairment charge for a Life Sciences trade name. Adjusted EPS of $1.94 rose 8.0% and beat the $1.8533 consensus by about $0.09. The gap between the two figures is mostly $0.65 of acquisition-related intangible amortization plus $0.15 of Masimo-related acquisition items.
Revenue of $6.265 billion rose 5.5% from $5.936 billion a year earlier, but only 3.0% of that was core growth once acquisitions and currency are stripped out. Excluding respiratory testing, core growth was 4.5%. Diagnostics grew 7.0% in total yet only 2.0% at the core, while Life Sciences delivered 5.5% core growth and Biotechnology managed 2.5%.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.